Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1 -Mutated AML

(2018) Yi Zhou et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations

(2018) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

(2018) Kiyomi Morita et al.   JOURNAL OF CLINICAL ONCOLOGY

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia

(2018) Maja Rothenberg-Thurley et al.   LEUKEMIA

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

(2018) Felicitas Thol et al.   BLOOD

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia

(2018) Laura W. Dillon et al.   HAEMATOLOGICA

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

(2017) Sarah A. Buckley et al.   HAEMATOLOGICA

Measurable residual disease testing in acute myeloid leukaemia

(2017) C S Hourigan et al.   LEUKEMIA

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis

(2017) Sarah A. Buckley et al.   HAEMATOLOGICA

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing

(2016) Erik B.R. Malmberg et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

When the Minimal Becomes Measurable

(2016) Christopher S. Hourigan et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?

(2016) Daisuke Araki et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

A multigene array for measurable residual disease detection in AML patients undergoing SCT

(2015) M Goswami et al.   BONE MARROW TRANSPLANTATION

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

(2015) Jeffery M. Klco et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

(2015) Houria Debarri et al.   Oncotarget

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

(2015) Nestor Ramos et al.   Journal of Clinical Medicine

Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia

(2014) W.-G. Tong et al.   HAEMATOLOGICA

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues

(2014) M Goswami et al.   LEUKEMIA

Value of routine ‘day 14’ marrow exam in newly diagnosed AML

(2014) T Yezefski et al.   LEUKEMIA

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

(2013) Monique Terwijn et al.   JOURNAL OF CLINICAL ONCOLOGY

Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia

(2013) V Vainstein et al.   LEUKEMIA

Minimal residual disease in acute myeloid leukaemia

(2013) Christopher S. Hourigan et al.   Nature Reviews Clinical Oncology

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia

(2012) Tod A. Morris et al.   LEUKEMIA RESEARCH

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

(2009) Daniela Cilloni et al.   JOURNAL OF CLINICAL ONCOLOGY

Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia

(2008) Kebede Hussein et al.   AMERICAN JOURNAL OF HEMATOLOGY

Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia

(2008) M. Yanada et al.   HAEMATOLOGICA